Therapeutic potential of the Akt inhibitor perifosine in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for metastatic head and neck cancer.

Yi-Dan Lin,Xiangguo Liu,Zhuo (Georgia) Chen,Ping Yue,Sagar Lonial,Dong M Shin,Fadlo R Khuri,Shi-Yong Sun
IF: 11.2
2007-01-01
Cancer Research
Abstract:2405 Lymph node metastases remain a long-term problem in the treatment of head and neck sqaumous cell carcinoma (HNSCC). In an effort to understand the biology of metastasis of HNSCC and to develop effective therapeutic regimens against metastatic HNSCC, we established highly metastatic HNSCC cell lines through in vivo selection (Zhang et al, Clin Exp Metastasis, 2006). Using gene array and Western blot analysis, we found that highly metastatic HNSCC cell lines exhibit increased levels of death receptor 5 (DR5), Fas-associated death domain (FADD), caspase-8, caspase-9, and the short form of c-FLIP (FLIPS). Moreover, these metastatic cell lines had decreased levels of the long form of c-FLIP (FLIPL) and undetectable levels of TRAIL. Accordingly, the metastatic HNSCC cell lines are relatively more sensitive than their parental non-metastatic cell line to exogenous TRAIL treatment. These results suggest that metastatic HNSCC cells retain the capacity to undergo death receptor-mediated apoptosis. Perifosine is the first oral alkylphospholipid with Akt-inhibitory activity and is being tested in phase II cancer clinical trials. We found that perifosine further upregulated DR5 expression and reduced c-FLIP levels in the metastatic HNSCC cell lines. Interestingly, the metastatic HNSCC cell lines were much more sensitive than their parental cell line to perifosine-induced apoptosis. Moreover, the combination of perifosine and TRAIL augmented induction of apoptosis in the metastatic HNSCC cells. Collectively, these data suggest that targeting activation of TRAIL/death receptor-mediated apoptosis by the combination of perifosine and TRAIL has therapeutic potential against metastatic HNSCC, thus warranting in vivo evaluation of the efficacy of the combination of perifosine and TRAIL for treatment of metastatic HNSCC. (Supported in part by GCC Distinguished Cancer Scholar award and DOD grant DAMD17-01-1-0689-BESCT)
What problem does this paper attempt to address?